Tirzepatide + B6
Compounded tirzepatide with vitamin B6 (pyridoxine) as a sterile injectable. A dual GIP/GLP-1 receptor agonist used with diet and activity for weight and glucose support.12 Including B6 with tirzepatide may reduce nausea for some patients compared to tirzepatide alone.34
Compounding required for medical necessity.
- Active ingredients
- Tirzepatide
- Form
- Injection
- Route
- Subcutaneous
Are you a prescriber?
Download a compounding order form for this medication with dose options and packaging choices.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. In the SURMOUNT-1 trial of the branded molecule, once-weekly tirzepatide produced substantial, sustained weight reduction versus placebo when combined with lifestyle measures.1
U.S. prescribing information for approved tirzepatide products describes use with a reduced-calorie diet and increased physical activity, and includes a boxed warning about thyroid C-cell tumors observed in rodents.2
This preparation includes pyridoxine hydrochloride (vitamin B6) as an additive. Vitamin B6 is being studied for nausea support in other clinical settings, including randomized and pooled pregnancy data.34 That research does not establish that adding B6 makes this compounded product more effective than tirzepatide alone, or that it prevents GLP-1-related stomach side effects.
Connect Wellness compounds this sterile injectable for patient-specific prescriptions when a compounded formulation is medically necessary. It is not an FDA-approved finished drug product. Your clinician sets dose, titration, and monitoring. Common class-related effects can include nausea, vomiting, diarrhea, constipation, and decreased appetite. Discuss personal or family history of medullary thyroid carcinoma or MEN2, pancreatitis risk, and other contraindications before use.
References
- Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387, 205-216
“In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight.”
- U.S. Food and Drug Administration (2025). ZEPBOUND (tirzepatide) injection, for subcutaneous use — Prescribing Information. FDA Prescribing Information
- Sahakian V et al. (1991). Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled study. Obstetrics & Gynecology, 78, 33-36
- Jayawardena R et al. (2023). The effects of pyridoxine (vitamin B6) supplementation in nausea and vomiting during pregnancy: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 308, 1075-1084